Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors | Precision Medicine

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.